With all the focus on Ramin’s statement that Unilife would not breakeven until 2018 to 2020 I wanted to present an example how little that can mean to the stock price. There are many metrics that can be used to analyze a company, but I assume that in the end most are concerned with the long term sustainability of the company and the stock price.
Insulet is focused on diabetes and insulin management through the use of it’s insulin pumps. The range of their products compared to Unilifes is very limited. There are many differences between Insulet and Unilife including the COG and SG&A and I believe that once we begin significant shipments, execution of our long term contracts, our revenue will grow even faster than Insulet’s did.
Below is a 5 year summary of key metrics for Insulet (PODD on the NASDAQ):
2009 2010 2011 2012 2013
Revenue 66 97 152 211 247
COG 48 53 89 125 140
Gross Income 18 44 63 86 108
SG&A N/A 78 100 122 124
Interest 13 23 13 16 17
Net LOSS 72 61 57 52 45
Stock Prices On Jan 1 7.84 15.03 16.07 19.06 21.49
All figures are in millions of USD except Stock Price.
On Jan1 2014 stock price was $35.83 current price is $45.83
Once we begin to actually show sales revenue I think we will see similar or greater share price growth.
- Forums
- ASX - By Stock
- UNS
- The sky's falling
The sky's falling, page-11
-
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add UNS (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
LPM
LITHIUM PLUS MINERALS LTD.
Simon Kidston, Non--Executive Director
Simon Kidston
Non--Executive Director
SPONSORED BY The Market Online